Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $196,542 | $59,606 | $3,686 | $0 |
| % Growth | 229.7% | 1,517.1% | – | – |
| Cost of Goods Sold | $19,128 | $4,987 | $754 | $763 |
| Gross Profit | $177,414 | $54,619 | $2,932 | -$763 |
| % Margin | 90.3% | 91.6% | 79.5% | – |
| R&D Expenses | $76,420 | $110,575 | $182,435 | $145,558 |
| G&A Expenses | $222,491 | $0 | $122,124 | $60,971 |
| SG&A Expenses | $229,391 | $185,145 | $122,124 | $60,971 |
| Sales & Mktg Exp. | $6,900 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $173 |
| Operating Expenses | $305,811 | $295,720 | $304,559 | $206,529 |
| Operating Income | -$128,397 | -$241,101 | -$301,627 | -$206,529 |
| % Margin | -65.3% | -404.5% | -8,183% | – |
| Other Income/Exp. Net | -$10,995 | -$17,926 | -$9,831 | $173 |
| Pre-Tax Income | -$139,392 | -$259,027 | -$311,458 | -$206,356 |
| Tax Expense | $647 | $3,113 | $0 | $0 |
| Net Income | -$140,039 | -$262,140 | -$311,458 | -$206,356 |
| % Margin | -71.3% | -439.8% | -8,449.8% | – |
| EPS | -1.16 | -3.78 | -5.66 | -4.17 |
| % Growth | 69.3% | 33.2% | -35.7% | – |
| EPS Diluted | -1.16 | -3.78 | -5.66 | -4.17 |
| Weighted Avg Shares Out | 120,958 | 69,305 | 55,032 | 49,406 |
| Weighted Avg Shares Out Dil | 120,958 | 69,305 | 55,032 | 49,406 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $173 |
| Interest Expense | $27,168 | $29,712 | $15,652 | $0 |
| Depreciation & Amortization | $2,599 | $1,881 | $1,253 | $763 |
| EBITDA | -$109,625 | -$227,434 | -$294,553 | -$205,593 |
| % Margin | -55.8% | -381.6% | -7,991.1% | – |